New obesity drug combo shows promise in early trial
NCT ID NCT06771115
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called VTX3232, given alone or with the weight-loss drug semaglutide, in 176 adults with obesity. The main goal was to check safety and side effects over 12 weeks. Researchers also measured changes in inflammation levels. The trial is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VTX3232 (an experimental drug) and semaglutide (a weight-loss drug)
What this could lead to
If successful, this could point toward a new treatment option for obesity that reduces inflammation and helps with weight loss.
What could go wrong
This is an early phase 2a trial focused on safety, not weight loss. The results may not lead to an approved treatment, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
840001
Largo, Florida, 33761, United States
-
840002
Austin, Texas, 78705, United States
-
840003
Lake Forest, California, 92630, United States
-
840005
Birmingham, Alabama, 35235, United States
-
840006
Dallas, Texas, 75230, United States
-
840010
Waco, Texas, 76710, United States
-
840011
Long Beach, California, 90815, United States
-
840012
Ocoee, Florida, 34761, United States
-
840013
San Antonio, Texas, 78229, United States
-
840014
Newton, Kansas, 67114, United States
-
840015
Marrero, Louisiana, 70072, United States
-
840016
Port Orange, Florida, 32127, United States
-
840017
Marrero, Louisiana, 70072, United States
-
840018
San Antonio, Texas, 78229, United States